ascopubs.org

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

In a longitudinal clinical study to compare two groups, the primary end point is often the time to a specific event (eg, disease progression, death). The hazard ratio estimate is routinely used to ...
Pulmonology Advisor

Lower 25(OH)D Linked to Higher Risk for Respiratory Tract Infection Hospitalization

Low serum 25-hydroxyvitamin D is associated with an increased risk for respiratory tract infection hospitalization.
ascopubs.org

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

We analyzed 54 randomized controlled trials totaling 33,212 patients. The selected outcome was overall survival in 21 (39%) trials. There was evidence of nonproportionality of hazards in 13 (24%) ...
Nasdaq

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already ...
Seeking Alpha

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in ...

This review of overall survival at 52% data maturity and a data cutoff of December 2023 noted a hazard ratio of 0.80 (95% CI: 0.59, 1.08). “The overall survival results of the HARMONi-A study evidence ...